Local Ablation in Pancreatic Cancer: Ongoing Trials and Investigative Directions

In the second part of this video series, Rebekah R. White, MD, FACS, and Zachary T. Berman, MD, both of the University of California, San Diego, consider how the post hoc analysis of the CROSSFIRE trial comparing percutaneous irreversible electroporation (IRE) with stereotactic body radiotherapy for locally advanced pancreatic cancer, along with other ongoing clinical trials, will provide further understanding of the benefit of combining ablative therapy with immunotherapy.

They also share what they hope to achieve with the opening of a new clinical trial that combines IRE with a CD40 agonist.

View their previous comments on Local Ablation in Pancreatic Cancer: IRE Versus SBRT.